Several studies support this phenomenon that inhibition of HDAC11 can possibly be a therapeutic target for the management of various brain disorders and different cancers in which HDAC11 is found to be more expressed (up to 4 %) (Liu et al., 2020[7]) (Supplementary Figure 1). Here, HDAC11 is linked to cancer.